Clinical Trials Browser

Phase EARLY_PHASE1 × Recruiting × Myasthenia Gravis × Clear all

Multiple Sclerosis, Myasthenia Gravis, Recurrence, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06939166 2025-12-15

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Recruiting

12 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT07058298 2025-09-08

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Phase EARLY_PHASE1 Recruiting

6 enrolled

Myasthenia Gravis

NCT04561557 2024-10-30

CARTinNS

Phase EARLY_PHASE1 Recruiting

36 enrolled

Plasma cell

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Autoimmune Diseases, Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, POEMS Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trials

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

CARTinNS